CHM.AX Chimeric Therapeutics (ASX) up 25% pre-market 24 Jan 2026: outlook
CHM.AX stock opened pre-market on 24 Jan 2026 at A$0.0025 after a one-day move of +25.0% from the previous close. The spike places Chimeric Therapeutics Limited (ASX) among the top gainers ahead of upcoming clinical and earnings catalysts. Traders are watching volume and clinical updates for CHM 0201 and CHM 1101, which connect directly to the share move and near-term outlook.
CHM.AX stock price action and immediate catalyst
Chimeric Therapeutics (CHM.AX) trades pre-market at A$0.0025, up 25.0% from the previous close of A$0.0020. This one-day rise reflects speculative buying ahead of a scheduled earnings announcement and possible trial updates.
The move is typical for small-cap biotech names on ASX. Average volume is materially higher historically at 7,837,558 shares, so watch for a true volume pick-up to confirm a sustained trend.
Company snapshot and clinical drivers for CHM.AX stock
Chimeric Therapeutics Limited is an Australian clinical-stage cell therapy company listed on the ASX. Its lead programs include CHM 0201 (NK platform) and CHM 1101 (CLTX CAR T) aimed at solid tumours and glioblastoma.
Clinical readouts or trial enrolment updates often move CHM.AX stock because pipeline progress materially changes valuation expectations for a micro-cap biotech with a market cap near A$8,837,400.
Financials and valuation context for CHM.AX stock
At current levels Chimeric reports negative earnings and limited cash per share. Latest data shows EPS: -0.01, PE: -0.2, price averages of A$0.00284 (50-day) and A$0.00369 (200-day). The company has 4,418,700,000 shares outstanding.
Key ratios highlight risk. The current ratio is 0.72 and research spend exceeds revenue, with R&D-to-revenue at 101.49%. These metrics explain why analysts treat CHM.AX stock as high risk and highly binary.
Meyka Grade and CHM.AX stock forecast
Meyka AI rates CHM.AX with a score out of 100: 62.11 / Grade B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a quarterly target of A$0.01, compared with the current price of A$0.0025, implying an upside of +300.00%. Forecasts are model-based projections and not guarantees.
Technicals, trading signals and sector comparison for CHM.AX stock
Technical indicators show muted trend strength with RSI 39.73 and ADX 16.50, signalling no clear momentum yet. Price sits below the 50‑day and 200‑day averages, reflecting a longer-term downtrend from the year high of A$0.009.
Healthcare sector dynamics are mixed. The ASX Healthcare average PE is 33.86, well above Chimeric’s metrics. That gap shows CHM.AX stock remains valued more on binary trial outcomes than on peer multiples.
Risks and opportunities shaping CHM.AX stock outlook
Opportunity: Positive phase I data or faster enrolment could re-rate CHM.AX stock significantly, given the low baseline price and modelled upside to A$0.01. Small-cap biotech rallies can be sharp if clinical proof points arrive.
Risk: Cash runway, low current ratio, and negative EPS create dilution risk. A weak clinical update could push price toward the year low of A$0.002 and amplify volatility.
Final Thoughts
CHM.AX stock is a high‑volatility, event-driven ASX micro-cap. The pre-market 25.0% jump to A$0.0025 on 24 Jan 2026 reflects trader positioning ahead of clinical and earnings catalysts. Meyka AI’s forecast model projects A$0.01 as a quarterly target, an implied +300.00% upside versus today. Our Meyka grade of 62.11 / B (HOLD) balances upside from potential trial progress against weak liquidity, low current ratio, and ongoing losses. Investors should treat CHM.AX stock as speculative, size positions accordingly, and watch for confirmed volume and clear clinical news before changing exposure. Meyka AI provides this as part of its AI-powered market analysis; forecasts are model-based and not guarantees.
FAQs
What moved CHM.AX stock pre-market today?
CHM.AX stock rose 25.0% pre-market on 24 Jan 2026 on speculative buying ahead of a clinical and earnings window. Volume and trial updates will determine if the move holds.
What is Meyka AI’s forecast for CHM.AX stock?
Meyka AI’s forecast model projects a quarterly target of A$0.01, implying about +300.00% from the current A$0.0025. Forecasts are model-based projections and not guarantees.
Is CHM.AX stock a buy for long-term investors?
CHM.AX stock is speculative. Meyka AI assigns a B (HOLD) grade, noting binary clinical risk, weak liquidity, and potential dilution. Long-term buy decisions need confirmed clinical progress and balance sheet improvement.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
